ÐÂÎÅ×ÊѶ
æÇÃÀGLP-1¶àëĹú¼ÊÃ÷ÐDzúÆ·£¡918²©ÌìÌöàëÄÐÂÒ©ÔÚ·ÊÅÖÖÎÁÆÁìÓòÈ¡µÃÁÙ´²Ç°ÐÂÍ»ÆÆ
ÈÕÆÚ£º
2026Äê04ÔÂ02ÈÕ 14:40
ÔÚ·ÊÅÖ¼°Ïà¹Ø´úлÐÔ¼²²¡³ÉΪȫÇòÐÔ¿µ½¡Ìôսȷµ±Ï£¬£¬£¬£¬£¬918²©ÌìÌã¨ÒÔϼò³Æ“918²©ÌìÌÔ£©´«À´Õñ·ÜÈËÐĵÄÐÂÎÅ£¡Æä×ÔÖ÷Ñз¢µÄÁ¢ÒìС·Ö×Ó»·ëÄÒ©ÎMCR»·ëÄ£©£¬£¬£¬£¬£¬ÔÚÕë¶ÔDB/DB·ÊÅÖСÊóÄ£×ÓµÄÁÙ´²Ç°Ñо¿ÖУ¬£¬£¬£¬£¬Õ¹ÏÖ³öÓÅÓÚÏÖÓÐÃ÷ÐÇÒ©ÎïGLP-1¶àëĵļõÖØЧ¹û£»£»£»£»£»£» £»ÍŽáÆä¶Ô¼¡ÈâµÄ¼á³Ö×÷Ó㬣¬£¬£¬£¬ÒÔ¼°¶ÔѪÌÇ¡¢ÑªÖ¬µÈ´úлָ±êµÄ×ۺϵ÷Àí×÷Ó㬣¬£¬£¬£¬ÓÐÍû´øÀ´²î±ð»¯µÄÁÙ´²Ñ¡Ôñ¡£¡£¡£¡£ ¡£¡£¡£¡£
Ò»¡¢¾ªÑ޵ļõÖØÊý¾Ý
DB/DBСÊóÊÇÑо¿·ÊÅÖºÍ2ÐÍÌÇÄò²¡µÄ¾µä¶¯ÎïÄ£×Ó£¬£¬£¬£¬£¬ÆäÓÉÓÚ»ùÒòÍ»±äµ¼ÖÂÊÝËØÊÜÌ幦ЧȱÏÝ£¬£¬£¬£¬£¬ÌåÏÖ³öÑÏÖصķÊÅÖ¡¢¸ßѪÌǺʹúлÔÓÂÒµÈÖ¢×´¡£¡£¡£¡£ ¡£¡£¡£¡£ÔÚ918²©ÌìÌÿªÕ¹µÄÕâÏîÁÙ´²Ç°Ñо¿ÖУ¬£¬£¬£¬£¬¹«Ë¾×ÔÑеÄС·Ö×Ó»·ëÄÕ¹ÏÖ³öÓÅÒìµÄ¼õÖØЧ¹û¡£¡£¡£¡£ ¡£¡£¡£¡£
ÊÔÑéЧ¹ûÏÔʾ£¬£¬£¬£¬£¬¾ÓÉΪÆÚ8ÖܵÄÖÎÁÆ£¬£¬£¬£¬£¬Óë¿Õȱ±ÈÕÕ×éDB/DBСÊóÏà±È£¬£¬£¬£¬£¬MCR»·ëĽϸ߼ÁÁ¿×éµÄСÊóµÄÌåÖØϽµ·ù¶ÈԼΪGLP-1¶àëÄ×éµÄ1.25±¶£¬£¬£¬£¬£¬Ê¹DB/DBСÊóµÄÌåÖØÔöÌíÇ÷ÊÆÏÔ×Å·Å»º£¬£¬£¬£¬£¬¿¿½ü¿µ½¡±ÈÕÕ×éˮƽ¡£¡£¡£¡£ ¡£¡£¡£¡£
¶þ¡¢¶àÏî´úлָ±êÖÜÈ«¸ÄÉÆ
MCR»·ëĽϸ߼ÁÁ¿×éÔÚ¸ÄÉƸÊÓÍÈýõ¥£¨TG£©¡¢¸ßÃܶÈÖ¬ÂÑ°×µ¨¹Ì´¼£¨HDL-C£©¡¢ÑªÌÇ¡¢ÄòÌÇˮƽ·½Ã棬£¬£¬£¬£¬Í¬ÑùÌåÏÖÓÅÒ죺
1.TGˮƽ£ºÏÔÖø½µµÍDB/DBСÊóµÄTGˮƽ£¬£¬£¬£¬£¬ÓÅÓÚGLP-1¶àëÄ×飻£»£»£»£»£» £»
2.HDL-Cˮƽ£ºÏÔ×ÅÉý¸ß£¬£¬£¬£¬£¬ÓÅÓÚGLP-1¶àëÄ×飻£»£»£»£»£» £»ÓÐÖúÓÚ½µµÍ¶¯ÂöÖàÑùÓ²»¯Î£º¦£»£»£»£»£»£» £»
3.ѪÌÇˮƽ£ºÖÎÁÆ6ÖܵĽµµÍѪÌÇŨ¶ÈˮƽÓëGLP-1¶àëÄ×é¿¿½ü£»£»£»£»£»£» £»
4.ÄòÌÇˮƽ£ºÖÎÁÆ8Öܽ«ÄòÌÇˮƽ´Ó»ùÏß½µÖÁÒ»°ë£»£»£»£»£»£» £»
5.ÌÇ»¯ÑªºìÂÑ°×£¨HbA1c£©£ºÓëÄ£×Ó×éÏà±È£¬£¬£¬£¬£¬HbA1cϽµ·ù¶È´ïÔ¼1/3¡£¡£¡£¡£ ¡£¡£¡£¡£
|ÍŽáDZÁ¦
ÖµµÃÒ»ÌáµÄÊÇ£¬£¬£¬£¬£¬918²©ÌìÌÃÒÑ¿ªÕ¹ÁË»·ëÄÓëGLP-1ÀàÒ©ÎÈçGLP-1¶àëÄ£©ÍŽáʹÓõÄÑо¿£¬£¬£¬£¬£¬Ð§¹ûÏÔʾÔÚÒûʳÓÕµ¼µÄ·ÊÅÖСÊóÄ£×ÓÖУ¬£¬£¬£¬£¬Á½ÕßÔÚ¼õÖØЧ¹û¼°¼¡Èâ±£»£»£»£»£»£» £»¤·½Ãæ¾ßÓÐÃ÷È·µÄÐͬЧӦ£º
1.Ðͬ¼õÖØ£ºÁªÊÊÓÃÒ©×éÌåÏÖ³ö¸üÏÔÖøµÄ¼õÖØЧ¹û£¬£¬£¬£¬£¬ÓÅÓÚµ¥Ò©ÖÎÁÆ£»£»£»£»£»£» £»
2.ïÔ̼¡ÈâÁ÷ʧ£º»·ëÄÔÚÁªÓÃÖÐÓÐÓûº½âGLP-1ÀàÒ©Îï´øÀ´µÄ¼¡ÈâÁ÷ʧÎÊÌ⣬£¬£¬£¬£¬Ìá¸ßÕûÌåÖÎÁÆÇå¾²ÐÔ¡£¡£¡£¡£ ¡£¡£¡£¡£
Èý¡¢¶à°ÐµãÐͬ×÷Ó㺻·ëĵÄÁ¢Òì»úÖÆ
MCR»·ëÄÖ®ÒÔÊÇÄܹ»ÔÚ¼õÖؼ°ÆäËû´úлָ±êÉÏÈ¡µÃÔÆÔÆÓÅÒìµÄЧ¹û£¬£¬£¬£¬£¬ÓëÆäÆæÒìµÄ×÷ÓûúÖÆÃܲ»¿É·Ö¡£¡£¡£¡£ ¡£¡£¡£¡£×÷ΪһÖÖС·Ö×Ó»·ëÄÒ©Î£¬£¬£¬£¬Äܹ»Í¬Ê±¾«×¼×÷ÓÃÓÚMC4RºÍMC1RÁ½¸öÒªº¦°Ðµã£¬£¬£¬£¬£¬Í¨¹ý¶à°ÐµãÐͬ×÷Ó㬣¬£¬£¬£¬Ê©Õ¹Æä׿ԽµÄ´úлµ÷Àí¹¦Ð§¡£¡£¡£¡£ ¡£¡£¡£¡£
|¼¤»îMC4R£ºÒÖÖÆʳÓû£¬£¬£¬£¬£¬Ôö½øÖ¬·¾ÆÊÎö
MC4RÊÇÖÐÊàÉñ¾ÏµÍ³µ÷¿ØÄÜÁ¿Æ½ºâµÄÒªº¦ÊÜÌå¡£¡£¡£¡£ ¡£¡£¡£¡£918²©ÌìÌÃMCR»·ëÄ×÷ΪMC4R¼¤¶¯¼Á£¬£¬£¬£¬£¬Äܹ»Ôö½øÖ¬·¾ÆÊÎö£¬£¬£¬£¬£¬ÒÖÖÆÖ¬·¾ÌìÉú£»£»£»£»£»£» £»Ôö½ø°×É«Ö¬·¾×éÖ¯ºÖ±ä£»£»£»£»£»£» £»Ìá¸ßÒȵºËØÃô¸ÐÐÔ£»£»£»£»£»£» £»ÔÚ²»ÏÔÖøÒÖÖÆʳÓûµÄÌõ¼þÏÂʵÏÖ¼õÖ¬£¬£¬£¬£¬£¬×èÖ¹Ñáʳ¸±×÷ÓÃ1¡£¡£¡£¡£ ¡£¡£¡£¡£
|¼¤»îMC1R:¿¹Ñ×ÃâÒßµ÷Àí£¬£¬£¬£¬£¬»Ö¸´ÊÝËØÃô¸ÐÐÔ
MC1RÖ÷Òª¼ÓÈëÃâÒßµ÷ÀíºÍÑ×Ö¢·´Ó¦¡£¡£¡£¡£ ¡£¡£¡£¡£Í¨¹ý¼¤»îMC1R£¬£¬£¬£¬£¬Äܹ»ÏÔÖø¸ÄÉÆÌåÄÚÑ×֢΢ÇéÐΣ¬£¬£¬£¬£¬½µµÍÑ×Ö¢Òò×Ó£¨°üÀ¨IL-1, TNF-a, IL-6, IL-8, and IL-12, iNOSµÈ£©µÄ±í´ï´Ó¶ø»Ö¸´ÊÝËØÃô¸ÐÐԺ͵÷ÀíÃâÒß·´Ó¦£¬£¬£¬£¬£¬¶Ô×ÔÉíÃâÒßÐÔ¼²²¡¾ßÓÐDZÔÚÖÎÁƼÛÖµ2¡£¡£¡£¡£ ¡£¡£¡£¡£
ËÄ¡¢ÁÉÀ«µÄÓ¦ÓÃÔ¶¾°£º´úлÔÓÂÒÓë×ÔÉíÃâÒß˳Ӧ֢
»ùÓÚMCR»·ëÄÔÚÁÙ´²Ç°Ñо¿ÖÐÕ¹ÏÖ³öµÄ׿Խ¼õÖØЧ¹ûºÍ¶àϵͳ´úл¸ÄÉÆ×÷Ó㬣¬£¬£¬£¬918²©ÌìÌöÔÆäδÀ´ÔÚ´úлºÍ×ÔÃâÁìÓòÖеÄÓ¦ÓÃÔ¶¾°³äÂúÐÅÐÄ¡£¡£¡£¡£ ¡£¡£¡£¡£
´úл×ÛºÏÕ÷¼°Æä²¢·¢Ö¢·½Ã棬£¬£¬£¬£¬MCR»·ëIJ»µ«ÄܼõÖØ£¬£¬£¬£¬£¬»¹ÄÜͬ²½¸ÄÉÆѪÌÇ¡¢ÑªÖ¬¡¢HbA1c¡¢ÄòÌǵȶàÏîÖ¸±ê£¬£¬£¬£¬£¬¶Ô2ÐÍÌÇÄò²¡¡¢·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡¡¢¸ßѪѹ¡¢¶¯ÂöÖàÑùÓ²»¯µÈ´úл×ÛºÏÕ÷×é·ÖÖ®Ò»»ò¶àÏî¾ßÓиÉԤDZÁ¦¡£¡£¡£¡£ ¡£¡£¡£¡£
×ÔÉíÃâÒßÓëÑ×Ö¢Ïà¹Ø¼²²¡·½Ã棬£¬£¬£¬£¬ÓÉÓÚÆä¾ß±¸ÏÔÖøµÄ¿¹Ñ׺ÍÃâÒßµ÷Àí×÷Ó㬣¬£¬£¬£¬Î´À´ÓÐÍûÍØÕ¹ÖÁÀà·çʪÐÔÊàŦÑ×£»£»£»£»£»£» £»ÂýÐÔÉö²¡£¡£¡£¡£ ¡£¡£¡£¡£¨CKD£©£»£»£»£»£»£» £»ÌÇÄò²¡Éö²¡£¡£¡£¡£ ¡£¡£¡£¡£¨DN£©µÈ˳Ӧ֢¡£¡£¡£¡£ ¡£¡£¡£¡£
½ÓÏÂÀ´£¬£¬£¬£¬£¬¹«Ë¾½«¼ÌÐøÍƶ¯¶àëÄÐÂÒ©µÄÁÙ´²Ç°Ò©ÀíѧºÍ¶¾ÀíѧÑо¿£¬£¬£¬£¬£¬ÕùÈ¡ÔçÈÕ½«ÐÂÒ©ÍÆÏòÁÙ´²½×¶Î£¬£¬£¬£¬£¬ÔÚÒÑÊÚȨµÄרÀû¼Ó³ÖÏ£¬£¬£¬£¬£¬¿ìËÙ½«²î±ð»¯µÄºÃÒ©´ø¸øÓµÓÐÏà¹ØÖÎÁÆÐèÇóµÄ»¼ÕßȺÌå¡£¡£¡£¡£ ¡£¡£¡£¡£
ÎÄÕÂȪԴÓÚҩʱ´ú¹«ÖÚºÅ
²Î¿¼ÎÄÏ×
1. Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022). Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal transduction and targeted therapy, 7(1), 298.https://doi.org/10.1038/s41392-022-01149-x
2. Mun, Y., Kim, W., & Shin, D. (2023). Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. International journal of molecular sciences, 24(15),12152. https://doi.org/10.3390/ijms241512152
Ïà¹ØÍƼö
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ̨ÖÝ